933986-40-4

Basic information

• Product Name: 1-(4-ethynylbenzyl)-4-methylpiperazine
• Synonyms: 1-(4-ethynylbenzyl)-4-methylpiperazine
• CAS NO: 933986-40-4
• Molecular Weight: 214.31
• Mol File: 933986-40-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-(4-ethynylbenzyl)-4-methylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-ethynylbenzyl)-4-methylpiperazine(933986-40-4)
• EPA Substance Registry System: 1-(4-ethynylbenzyl)-4-methylpiperazine(933986-40-4)

Safety Data

• Hazardous Substances Data: 933986-40-4(Hazardous Substances Data)

Usage

Chemical structure

A piperazine ring with a 4-methyl substituent and a 4-ethynylbenzyl substituent.

Classification

Substituted piperazine derivative.

Central nervous system targeting

Potential drug for neurological and psychiatric disorders.

Drug development

Used in the development of new drugs and pharmaceutical compounds.

Neurotransmitter modulation

Has the potential to modulate the activity of neurotransmitters in the brain.

Importance in research

Crucial compound in the field of drug development and neuroscience research.

Upstream product

• 945762-01-6 N-methoxy-N-methyl-4-(4-methyl-piperazin-1-ylmethyl)-benzamide 
• 106261-48-7 4-(4-methylpiperazin-1-ylmethyl)benzoic acid 
• 439691-80-2 4-((4-methylpiperazin-1-yl)methyl)benzaldehyde 
• 90965-06-3 dimethyl 1-(1-diazo-2-oxopropyl)phosphonate 
• 63697-96-1 4-Ethynylbenzaldehyde 
• 10602-04-7 (4-ethynylphenyl)methanol 
• 109-01-3 1-methyl-piperazine 
• 10601-98-6 1-(Chloromethyl)-4-ethynylbenzene 

Downstream Products

• 1346617-86-4 N-[2-methyl-5-(4-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-1H-1,2,3-triazol-1-yl)phenyl]-4-(pyridine-3-yl)pyrimidin-2-amine 
• 1346617-87-5 N-[2-methyl-5-(4-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-1H-1,2,3-triazol-1-yl)phenyl]-4-phenylpyrimidin-2-amine 

Relevant articles and documents

Syntheses and biological evaluation of 1,2,3-triazole and 1,3,4-oxadiazole derivatives of imatinib

Three novel series of 1,2,3-triazole and 1,3,4-oxadiazole derivatives of imatinib were prepared and evaluated in vitro for their cytostatic effects against a human chronic myeloid leukemia (K562), acute myeloid leukemia (HL60), and human leukemia stem-like cell line (KG1a). The structure-activity relationship was analyzed by determining the inhibitory rate of each imatinib analog. Benzene and piperazine rings were necessary groups in these compounds for maintaining inhibitory activities against the K562 and HL60 cell lines. Introducing a trifluoromethyl group significantly enhanced the potency of the compounds against these two cell lines. Surprisingly, some compounds showed significant inhibitory activities against KG1a cells without inhibiting common leukemia cell lines (K562 and HL60). These findings suggest that these compounds are able to inhibit leukemia stem-like cells.

2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PREPARATION METHOD AND USE THEREOF

Provided in the present invention are a 2-arylbenzofuran-7-formamide compound as shown in general formula I or a pharmacologically or physiologically acceptable salt thereof, a preparation method thereof and use thereof in preparing anti-tumour drugs, whe

N-[2-methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine as a Scaffold for the synthesis of inhibitors of Bcr-Abl

N-[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine derivatives were synthesized and evaluated invitro for their potential use as inhibitors of Bcr-Abl. The design is based on the bioisosterism between the 1,2,3-triazole ring and the amide group. The synthesis involves a copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) as the key step, with the exclusive production of anti-(1,4)-triazole derivatives. One of the compounds obtained shows general activity similar to that of imatinib; in particular, it was observed to be more effective in decreasing the fundamental function of cdc25A phosphatases in the K-562 cell line. Willing and Abl inhibitors! N-[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine derivatives were synthesized by a copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) as a key step, with anti-(1,4)-triazole derivatives as the exclusive products. One of these compounds shows general activity similar to that of imatinib, and in particular, it is more effective in decreasing the fundamental function of cdc25A phosphatases in the K-562 cell line.